natgillin/translations-raw huggingface dataset:
Patients treated for persistent, recurrent, or metastatic cervical cancer with bevacizumab are at increased risk of fistulae between the vagina and any part of the GI tract (Gastrointestinal-vaginal fistulae). 
Pri bolnicah z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu, ki se zdravijo z bevacizumabom, obstaja povečano tveganje za nastanek fistule med nožnico in katerimkoli delom prebavil (fistule med prebavili in nožnico).
(14.9 vs. 17.5 months; p = 0.4146) 
(14,9 meseca v primerjavi s 17,5 meseca; p = 0,4146)
In patients developing PRES, treatment of specific symptoms including control of hypertension is recommended along with discontinuation of Zirabev. 
Če se pri bolnikih pojavi PRES, je poleg prekinitve zdravljenja z zdravilom Zirabev priporočljivo zdravljenje specifičnih simptomov, vključno z obvladovanjem hipertenzije.
• NO16966: Bevacizumab 7.5 mg/kg of body weight every 3 weeks in combination with oral capecitabine and intravenous oxaliplatin (XELOX) or bevacizumab 5 mg/kg every 2 weeks in combination with leucovorin plus 5-fluorouracil bolus, followed by 5-fluorouracil infusion, with intravenous oxaliplatin (FOLFOX-4). 
NO16966: bevacizumab 7,5 mg/kg telesne mase vsake 3 tedne v kombinaciji s kapecitabinom peroralno in oksaliplatinom intravensko (shema XELOX) ali bevacizumab 5 mg/kg telesne mase vsaka 2 tedna v kombinaciji z levkovorinom in bolusom 5-fluorouracila, čemur je sledila infuzija 5-fluorouracila z intravensko danim oksaliplatinom (shema FOLFOX-4).
Aneurysms and artery dissections, Renal thrombotic microangiopathy a,b 
, globoka venska tromboza anevrizme in disekcije arterij, renalna trombotična mikroangiopatija a,b
Hypersensitivity, Infusion reactions a,b,c 
Bolezni imunskega sistema preobčutljivost, reakcije na infuzijo a,b,c
Hypersensitivity, Infusion reactions a,b,d 
Bolezni imunskega sistema preobčutljivost, reakcije na infuzijo a,b,d
Number of patients Progression-free survival 
Preživetje brez napredovanja bolezni
In a trial of patients with persistent, recurrent or metastatic cervical cancer, the incidence of GI-vaginal fistulae was 8.3% in bevacizumab-treated patients and 0.9% in control patients, all of whom had a history of prior pelvic radiation. 
V preskušanju pri bolnicah z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu je bila pojavnost fistul med prebavili in nožnico 8,3 % pri bolnicah, ki so se zdravile z bevacizumabom, in 0,9 % pri bolnicah v kontrolni skupini; vse te bolnice so imele v anamnezi obsevanje medeničnega predela.
The primary endpoint was overall survival, with secondary endpoints for the trial including progression-free survival. 
Primarni opazovani dogodek je bilo celokupno preživetje, sekundarni opazovani dogodki preskušanja pa so vključevali tudi preživetje brez napredovanja bolezni.
B-cell lymphoma when receiving bevacizumab with a cumulative doxorubicin dose greater than 300 mg/m2. 
V kliničnem preskušanju pri bolnikih z difuznim velikoceličnim B-limfomom, ki so prejemali bevacizumab skupaj s kumulativnim odmerkom doksorubicina, večjim od 300 mg/m2, so opazili večjo pojavnost KSP.
Bevacizumab may impair female fertility (see sections 4.6 and 4.8). 
Bevacizumab lahko zmanjša plodnost pri ženskah (glejte poglavji 4.6 in 4.8).
Hypertensive encephalopathy (very rare) (see also section 4.4 and Hypertension in section 4.8) 
Bolezni živčevja hipertenzivna encefalopatija (zelo redko) (glejte tudi poglavje 4.4 in ''Hipertenzija'' v poglavju 4.8) sindrom posteriorne reverzibilne encefalopatije (PRES - posterior reversible encephalopathy syndrome) (redko) (glejte tudi poglavje 4.4)
• Non-inferiority of the XELOX-containing arms compared with the FOLFOX-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival and overall survival in the eligible per-protocol population. 
● V populaciji, ki je bila primerna glede na protokol, so v celokupni primerjavi dokazali neinferiornost skupin, ki so se zdravile po shemi XELOX, v primerjavi s skupinami, ki so se zdravile po shemi FOLFOX-4, v smislu preživetja brez napredovanja bolezni in celokupnega preživetja.
6.3 Shelf life Vial (unopened) 
Viala (neodprta)
Patients treated with bevacizumab have an increased risk of haemorrhage, especially tumour-associated haemorrhage. 
Pri bolnikih, ki se zdravijo z bevacizumabom, obstaja povečano tveganje za krvavitev, zlasti za krvavitev, povezano s tumorjem.
d Recto-vaginal fistulae are the most common fistulae in the GI-vaginal fistula category. 
Rektovaginalne fistule so najpogostejše fistule v skupini fistul med prebavili in nožnico.
Aneurysms and artery dissections, Renal thrombotic microangiopathy b,c 
, globoka venska tromboza anevrizme in disekcije arterij, renalna trombotična mikroangiopatija b,c
Fistula b,d 
b,d krvavitev b,d
Zirabev should be discontinued in patients with life-threatening (Grade 4) thromboembolic reactions, including pulmonary embolism (NCI-CTCAE v.3). 
Pri bolnikih z življenjsko ogrožajočimi (stopnja 4) trombemboličnimi dogodki, vključno s pljučno embolijo (NCI-CTCAE v.3), je treba zdravljenje z zdravilom Zirabev prekiniti.
Patients were randomised to platinum-based chemotherapy (paclitaxel 200 mg/m2) and carboplatin AUC = 6.0, both by intravenous infusion (PC) on day 1 of every 3-week cycle for up to 6 cycles or 
Bolnike so randomizirali na kemoterapijo na osnovi platine (paklitaksel 200 mg/m2) in karboplatin z vrednostjo površine pod krivuljo (AUC) 6,0, pri čemer so bolniki oboje prejemali v obliki i.v.
The addition of bevacizumab 5 mg/kg every two weeks to 5-FU/FA resulted in higher objective response rates, significantly longer progression-free survival, and a trend in longer survival as compared to 5-FU/FA chemotherapy alone. 
Dodajanje bevacizumaba v odmerku 5 mg/kg vsaka 2 tedna shemi 5-FU/FA je povečalo objektivni odziv na zdravljenje in pomembno podaljšalo preživetje brez napredovanja bolezni.
Progression-free survival Median time (months) Hazard ratio p-value 
Preživetje brez napredovanja bolezni mediani čas (meseci) razmerje ogroženosti p-vrednost
Proteinuria b,d 
Bolezni sečil proteinurija b,d
Number of patients Overall survival Median (months) Hazard ratio 
Število bolnikov celokupno preživetje mediana (meseci) razmerje ogroženosti
(17.5 vs.14.3 months; p = 0.0609) 
(17,5 meseca v primerjavi s 14,3 meseca; p = 0,0609)
What Zirabev is and what it is used for What you need to know before you use Zirabev How to use Zirabev 
Kaj je zdravilo Zirabev in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Zirabev Kako uporabljati zdravilo Zirabev Možni neželeni učinki
You should seek help as soon as possible if you suffer from any of the below mentioned side effects. 
Če imate kateregakoli od spodaj navedenih neželenih učinkov, čim prej poiščite pomoč.
In a randomized phase II study (BO25041) a total of 121 patients aged ≥ 3 years to <18 years with newly diagnosed supratentorial or infratentorial cerebellar or peduncular high-grade glioma (HGG) 
V randomizirani študiji 2. faze (BO25041) so s pooperativnim obsevalnim zdravljenjem (RTradiotherapy) in adjuvantnim zdravljenjem s temozolomidom (T) v kombinaciji z intravensko danim bevacizumabom v odmerku 10 mg/kg vsaka 2 tedna ali brez njega zdravili skupno 121 bolnikov, starih od ≥ 3 let do < 18 let, z novo diagnosticiranim supratentorialnim ali infratentorialnim cerebelarnim ali pedunkularnim gliomom visoke stopnje (HGG - high-grade glioma).
a patients with measurable disease at baseline 
a bolniki z merljivo boleznijo ob izhodišču
Therefore fertility preservation strategies should be discussed with women of child-bearing potential prior to starting treatment with Zirabev. 
Pred začetkom zdravljenja z zdravilom Zirabev se je treba z ženskami v rodni dobi pogovoriti o strategijah za ohranitev plodnosti.
Myocardial infarction was reported in up to 1.4% of patients treated with bevacizumab in combination with chemotherapy compared to up to 0.7% of patients treated with chemotherapy alone. 
O miokardnem infarktu so poročali pri največ 1,4 % bolnikov, ki so se zdravili z bevacizumabom v kombinaciji s kemoterapijo, v primerjavi z največ 0,7 % bolnikov, ki so se zdravili samo s kemoterapijo.
One hundred and five patients were randomised to 5-FU/FA + placebo arm and 104 patients to 5-FU/FA + bevacizumab (5 mg/kg every 2 weeks) arm. All treatments were continued until disease progression. 
Skupno 105 bolnikov so randomizirali na prejemanje 5-FU/FA + placebo, 104 bolnike pa na prejemanje 5-FU/FA + bevacizumab (5 mg/kg vsaka 2 tedna).
Patients may be at risk of developing venous thromboembolic reactions, including pulmonary embolism under bevacizumab treatment. 
Med zdravljenjem z bevacizumabom pri bolnikih lahko obstaja tveganje za pojav venskih trombemboličnih dogodkov, vključno s pljučno embolijo.
Paclitaxel 135 mg/m2 intravenous over 24 hours on Day 1 and cisplatin 50 mg/m2 intravenous on Day 2 plus bevacizumab 15 mg/kg intravenous on Day 2 (q3w); or Paclitaxel 175 mg/m2 intravenous over 3 hours on Day 1 and cisplatin 50 mg/m2 intravenous on Day 2 plus bevacizumab 15 mg/kg intravenous on Day 2 (q3w); or Paclitaxel 175 mg/m intravenous over 3 hours on Day 1 and cisplatin 50 mg/m intravenous on Day 1 plus bevacizumab 15 mg/kg intravenous on Day 1 (q3w) 
• paklitaksel 135 mg/m2 intravensko v 24-urni infuziji na 1. dan in cisplatin 50 mg/m intravensko na 2. dan ter bevacizumab 15 mg/kg intravensko na 2. dan (vsake 3 tedne); ali paklitaksel 175 mg/m2 intravensko v 3-urni infuziji na 1. dan in cisplatin 50 mg/m intravensko na 2. dan ter bevacizumab 15 mg/kg intravensko na 2. dan (vsake 3 tedne); ali paklitaksel 175 mg/m2 intravensko v 3-urni infuziji na 1. dan in cisplatin 50 mg/m intravensko na 1. dan ter bevacizumab 15 mg/kg intravensko na 1. dan (vsake 3 tedne)
If you have high blood pressure which is not well controlled with blood pressure medicines, please consult your doctor as it is important to make sure that your blood pressure is under control before starting Zirabev treatment. 
Če imate visok krvni tlak, ki ga ne obvladujete v zadostni meri z zdravili proti povišanemu krvnemu tlaku, se posvetujte z zdravnikom.
In clinical trials of ovarian cancer, Grade 3-5 wound healing complications were observed in up to 1.8% of patients in the bevacizumab arm versus 0.1% in the control arm (NCI-CTCAE v.3). 
V kliničnih preskušanjih pri bolnicah z rakom jajčnikov so zaplete pri celjenju ran stopnje 3-5 opazili pri največ 1,8 % bolnic v skupini, ki je prejemala bevacizumab, v primerjavi z 0,1 % bolnic v kontrolni skupini (NCI-CTCAE v.3).
Česká Republika Pfizer, spol. 
Česká Republika Pfizer s.r.o.
Zirabev in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. 
Zdravilo Zirabev je v kombinaciji s paklitakselom indicirano za prvo linijo zdravljenja odraslih bolnikov z metastatskim rakom dojk.
Zirabev is also used for the treatment of adult patients with metastatic breast cancer. 
Zdravilo Zirabev uporabljamo tudi za zdravljenje odraslih bolnikov z metastatskim rakom dojk.
If the first infusion is well tolerated, the second infusion may be administered over 60 minutes. 
Če bolnik prvo infuzijo dobro prenese, lahko naslednjo infuzijo dajemo 60 minut.
Posterior Reversible Encephalopathy Syndrome (PRES), (rare) (see also section 4.4) 
Sindrom posteriorne reverzibilne encefalopatije (PRES - posterior reversible encephalopathy syndrome) (glejte poglavje 4.8)
This was a phase III randomised, double-blind, active-controlled clinical trial evaluating bevacizumab in combination with IFL as first-line treatment for metastatic carcinoma of the colon or rectum. 
To je bilo randomizirano, dvojno slepo, z učinkovino nadzorovano klinično preskušanje 3. faze, v katerem so ocenjevali bevacizumab v kombinaciji z IFL kot prvo linijo zdravljenja metastatskega raka debelega črevesa in danke.
Cisplatin/Gemcitabine + bevacizumab 15 mg/kg q 3 weeks 
Cisplatin in gemcitabin + bevacizumab 15 mg/kg vsake 3 tedne
Please discuss this with your doctor if you have metastatic cancer affecting your brain. 
Če imate metastatski rak, ki je prizadel vaše možgane, se o tem posvetujte z zdravnikom.
A dental examination and appropriate preventive dentistry should be considered prior to starting the treatment with Zirabev. 
Pred začetkom zdravljenja z zdravilom Zirabev je treba razmisliti o pregledu zobovja in ustreznih preventivnih zobozdravstvenih posegih.
• blockage in the gut or bowel, 
• zamašitev v črevesju ali prebavilih,
Proteinuria a,b 
Bolezni sečil proteinurija a,b
Progression-free survival Median (months) 
Preživetje brez napredovanja bolezni mediana (meseci)
● Zirabev can increase the risk of developing a weak heart. 
● Zdravilo Zirabev lahko poveča tveganje za popuščanje srca.
• fever, 
• vročino,
Best overall response - Primary analysis 
Najboljši celokupni odziv - primarna analiza bolnice z odzivom na zdravljenje (stopnja odziva
This was a phase III randomised, double-blind (for bevacizumab), clinical trial investigating bevacizumab 7.5 mg/kg in combination with oral capecitabine and intravenous oxaliplatin (XELOX), administered on a 3- weekly schedule; or bevacizumab 5 mg/kg in combination with leucovorin with 5-fluorouracil bolus, followed by 5-fluorouracil infusional, with intravenous oxaliplatin (FOLFOX-4), administered on a 2-weekly schedule. 
To je bilo randomizirano, dvojno slepo (za bevacizumab) klinično preskušanje 3. faze, v katerem so proučevali bevacizumab v odmerku 7,5 mg/kg v kombinaciji s peroralno danim kapecitabinom in intravensko danim oksaliplatinom (shema XELOX), kar so bolniki prejemali vsake 3 tedne; oziroma bevacizumab v odmerku 5 mg/kg v kombinaciji z levkovorinom in bolusom 5-fluorouracila, čemur je sledila infuzija 5-fluorouracila z intravensko danim oksaliplatinom (shema FOLFOX-4), kar so bolniki prejemali vsaka 2 tedna.
This was a phase II randomised, active-controlled, open-labelled clinical trial investigating bevacizumab in combination with 5-FU/FA as first-line treatment of metastatic colorectal cancer. 
To je bilo randomizirano, z učinkovino nadzorovano, odprto klinično preskušanje 2. faze , v katerem so proučevali bevacizumab v kombinaciji s shemo 5-FU/FA kot prvo linijo zdravljenja metastatskega raka debelega črevesa in danke.
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG-0240), grade 3-5 venous thromboembolic events have been reported in up to 15.6% of patients treated with bevacizumab in combination with paclitaxel and cisplatin compared with up to 7.0% of patients treated with paclitaxel and cisplatin. 
V kliničnem preskušanju pri bolnicah z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu (študija GOG-0240) so o venskih trombemboličnih dogodkih stopnje 3-5 poročali pri največ 15,6 % bolnic, ki so se zdravile z bevacizumabom v kombinaciji s paklitakselom in cisplatinom, v primerjavi z največ 7,0 % bolnic, ki so se zdravile s paklitakselom in cisplatinom.
In clinical trials, the overall incidence of arterial thromboembolic reactions ranged up to 3.8% in the bevacizumab containing arms compared with up to 2.1% in the chemotherapy control arms. 
V kliničnih preskušanjih je bila celokupna pojavnost arterijskih trombemboličnih dogodkov pri bolnikih v skupinah, ki so prejemale bevacizumab, največ 3,8 %, v kontrolnih skupinah, ki so prejemale kemoterapijo, pa največ 2,1 %.
Overall survival Median (months) Hazard ratio 95% CI 
Celokupno preživetje mediana (meseci) razmerje ogroženosti 95 % IZ
• Haemorrhage, including pulmonary haemorrhage/haemoptysis, which is more common in non- small cell lung cancer patients (see section 4.4). 
perforacije prebavil (glejte poglavje 4.4), krvavitev, vključno s krvavitvijo v pljučih/hemoptizo, ki je pogostejša pri bolnikih z nedrobnoceličnim rakom pljuč (glejte poglavje 4.4), arterijska trombembolija (glejte poglavje 4.4).
You should seek help immediately if you suffer from any of the below mentioned side effects. 
Če imate kateregakoli od spodaj navedenih neželenih učinkov, nemudoma poiščite pomoč.
Zirabev will be administered in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy. 
Zdravilo Zirabev boste prejeli v kombinaciji s paklitakselom in cisplatinom ali, če ste bolnica, ki ne more prejemati zdravljenja s platino, s paklitakselom in topotekanom.
Systemic adverse reactions including non-ocular haemorrhages and arterial thromboembolic reactions have been reported following intravitreal injection of VEGF inhibitors. 
Po intravitrealnem injiciranju zaviralcev VEGF so poročali o sistemskih neželenih učinkih, vključno s krvavitvijo izven predela oči in arterijskimi trombemboličnimi dogodki.
Asthenia, Fatigue, 
• utrujenost,
Median (months) 
Opazovani dogodek (meseci)
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG-0240), grade 3-5 infections have been reported in up to 24% of patients treated with bevacizumab in combination with paclitaxel and topotecan compared with up to 13% of patients treated with paclitaxel and topotecan. 
V kliničnem preskušanju pri bolnicah z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu (študija GOG-0240) so o okužbah stopnje 3-5 poročali pri največ 24 % bolnic, ki so se zdravile z bevacizumabom v kombinaciji s paklitakselom in topotekanom, v primerjavi z največ 13 % bolnic, ki so se zdravile s paklitakselom in topotekanom.
Seventy-one patients were randomised to receive bolus 5-FU/FA or 5-FU/FA + bevacizumab (5 mg/kg every 2 weeks). 
Randomizirali so 71 bolnikov, in sicer na prejemanje bolusa 5-FU/FA ali 5-FU/FA + bevacizumab (5 mg/kg vsaka 2 tedna).
● a blood clot in the blood vessels of your lungs, 
● krvni strdek v krvnih žilah pljuč,
Caution should be exercised when treating patients with clinically significant cardiovascular disease such as pre-existing coronary artery disease, or congestive heart failure with Zirabev. 
Pri bolnikih s klinično pomembno srčno-žilno boleznijo, kot sta obstoječa bolezen koronarnih arterij ali kongestivno srčno popuščanje, je pri zdravljenju z zdravilom Zirabev potrebna previdnost.
Eye disorder, Lacrimation increased 
Očesne bolezni očesna bolezen, močnejše solzenje
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG-0240), grade 3-5 bleeding reactions have been reported in up to 8.3% of patients treated with bevacizumab in combination with paclitaxel and topotecan compared with up to 4.6% of patients treated with paclitaxel and topotecan. 
V kliničnem preskušanju pri bolnicah z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu (študija GOG-0240) so o krvavitvah stopnje 3-5 poročali pri največ 8,3 % bolnic, ki so se zdravile z bevacizumabom v kombinaciji s paklitakselom in topotekanom, v primerjavi z največ 4,6 % bolnic, ki so se zdravile s paklitakselom in topotekanom.
Paclitaxel/ bevacizumab (n=252) 
paklitaksel in bevacizumab (n = 252)
Death of bone tissue (osteonecrosis) in bones other than the jaw have been reported in patients under 18 years old when treated with bevacizumab. 
Pri bolnikih, mlajših od 18 let, ki so se zdravili z bevacizumabom, so poročali o propadanju kostnega tkiva (osteonekrozi) v kosteh, razen v čeljustnici.
Zirabev is also used for the treatment of adult patients with advanced non-small cell lung cancer. 
Zdravilo Zirabev uporabljamo tudi za zdravljenje odraslih bolnikov z napredovalim nedrobnoceličnim rakom pljuč.
Patients may be at increased risk for the development of fistulae when treated with bevacizumab. 
Pri bolnikih, ki se zdravijo z bevacizumabom, lahko obstaja povečano tveganje za nastanek fistule.
The recommended dose of Zirabev is 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion. 
Priporočeni odmerek zdravila Zirabev je 7,5 mg/kg ali 15 mg/kg telesne mase v enkratnem odmerku vsake 3 tedne v obliki intravenske infuzije.
The median overall survival was 20.3 months in placebo and 21.2 months in bevacizumab treated patients in the FOLFOX treatment subgroup, HR=0.94, 97.5% CI = [0.75; 1.16]; p-value = 0.4937, the corresponding results in the XELOX, treatment subgroup being 19.2 vs. 21.4 months, HR = 0.84, 97.5% CI = [0.68; 1.04]; p-value = 0.0698. 
Mediano celokupno preživetje je bilo v podskupini, ki se je zdravila po shemi FOLFOX, 20,3 meseca pri bolnikih, ki so prejemali placebo, in 21,2 meseca pri bolnikih, ki so se zdravili z bevacizumabom; HR = 0,94; 97,5 % IZ = [0,75; 1,16]; p-vrednost = 0,4937.
If a dose of Zirabev is missed 
Če ste izpustili odmerek zdravila Zirabev:
5-fluorouracil intravenous bolus/infusion, each on days 1 and 2 
bolus/infuzija, oboje 1. in 2. dan placebo ali bevacizumab
Therapy should be permanently discontinued in patients who develop nephrotic syndrome (NCI-CTCAE v.3). 
Pri bolnikih, pri katerih se pojavi nefrotski sindrom (NCI-CTCAE v.3), je treba zdravljenje trajno prekiniti.
4.5 Interaction with other medicinal products and other forms of interaction Effect of antineoplastic agents on bevacizumab pharmacokinetics 
Vpliv zdravil z delovanjem na novotvorbe na farmakokinetiko bevacizumaba
In the FOLFOX treatment subgroup, the median PFS was 8.6 months in placebo and 9.4 months in bevacizumab treated patients, HR = 0.89, 97.5% CI = [0.73; 1.08]; p-value = 0.1871, the corresponding results in the XELOX treatment subgroup being 7.4 vs. 9.3 months, HR = 0.77, 97.5% CI = [0.63; 0.94]; p-value = 0.0026. 
V podskupini, ki se je zdravila po shemi FOLFOX, je bilo mediano PFS 8,6 meseca pri bolnikih, ki so prejemali placebo, in 9,4 meseca pri bolnikih, ki so se zdravili z bevacizumabom; razmerje ogroženosti (HR - hazard ratio) = 0,89; 97,5 % IZ = [0,73; 1,08]; p-vrednost = 0,1871.
Age was not associated with the pharmacokinetics of bevacizumab when body weight was taken into account. 
Starost ob upoštevanju telesne mase ni bila povezana s farmakokinetiko bevacizumaba.
Other special populations Elderly patients 
Starejši bolniki
In one clinical trial evaluating bevacizumab in combination with 5-fluorouracil/folinic acid, AVF2192g, patients with metastatic colorectal cancer who were not candidates for treatment with irinotecan were included. 
Bolnike z metastatskim rakom debelega črevesa in danke, ki niso bili primerni za zdravljenje z irinotekanom, so vključili v klinično preskušanje AVF2192g, v katerem so ocenjevali bevacizumab v kombinaciji s 5-fluorouracilom in folinsko kislino.
Paclitaxel/ bevacizumab (n=229) 
paklitaksel in bevacizumab (n = 229)
First-line treatment of non-squamous NSCLC in combination with platinum-based chemotherapy Zirabev is administered in addition to platinum-based chemotherapy for up to 6 cycles of treatment followed by Zirabev as a single agent until disease progression. 
Zdravilo Zirabev uporabljamo kot dodatek kemoterapiji na osnovi platine v obdobju največ 6 ciklov zdravljenja, nato pa zdravilo Zirabev uporabljamo samostojno do napredovanja bolezni.
200 mg/m2 intravenous 2 h 
2 uri 200 mg/m 2 i.v.
Paclitaxel 135 mg/m intravenous over 24 hours on Day 1 and cisplatin 50 mg/m intravenous on Day 2, every 3 weeks (q3w); or Paclitaxel 175 mg/m2 intravenous over 3 hours on Day 1 and cisplatin 50 mg/m2 intravenous on Day 2 (q3w); or 
• paklitaksel 135 mg/m 2 intravensko v 24-urni infuziji na 1. dan in cisplatin 50 mg/m intravensko na 2. dan (vsake 3 tedne); ali paklitaksel 175 mg/m 2 intravensko v 3-urni infuziji na 1. dan in cisplatin 50 mg/m intravensko na 2. dan (vsake 3 tedne); ali paklitaksel 175 mg/m 2 intravensko v 3-urni infuziji na 1. dan in cisplatin 50 mg/m intravensko na 1. dan (vsake 3 tedne)
Nasal septum perforation (not known) Pulmonary hypertension (not known) Dysphonia (common) 
Bolezni dihal, prsnega koša in mediastinalnega prostora perforacija nosnega pretina (neznana) pljučna hipertenzija (neznana) disfonija (pogosto)
Zirabev should be discontinued permanently in patients who experience Grade 3 or 4 bleeding during Zirabev therapy (NCI-CTCAE v.3) (see section 4.8). 
Pri bolnikih, pri katerih se med zdravljenjem z zdravilom Zirabev pojavi krvavitev stopnje 3 ali 4 (NCI-CTCAE v.3), je treba zdravljenje z zdravilom Zirabev trajno prekiniti (glejte poglavje 4.8).